Johnson & Johnson invests $1B+ in Montgomery County cell and gene therapy plant

J&J ramps U.S. advanced‑therapy manufacturing

Next‑generation cell and gene plant in Montgomery County

Johnson & Johnson is investing more than $1 billion to build a next‑generation cell and gene therapy manufacturing facility in Montgomery County, Pennsylvania, as it expands U.S. capacity for advanced cell therapy technologies. The plant is designed to support the company’s pipeline in cancer, immune‑mediated and neurological diseases and to deploy cutting‑edge manufacturing processes that J&J says will accelerate delivery of transformational medicines to patients.

The facility will employ more than 500 skilled biomanufacturing workers when fully operational and generate over 4,000 construction jobs during the build, the company says. The move deepens J&J’s footprint in Pennsylvania, where it already runs ten facilities covering more than 2 million square feet and reports roughly $10 billion in annual economic impact, and forms part of a broader $55 billion commitment to U.S. manufacturing, research and development and technology spending through early 2029.

Joaquin Duato, J&J’s chief executive, frames the investment as a continuation of the company’s 140‑year presence in American healthcare, saying it unites scientific R&D with state‑of‑the‑art manufacturing and strategic investment while delivering for patients and creating workforce opportunities. Pennsylvania Governor Josh Shapiro welcomes the project, saying it underscores the state’s strength in life sciences and advanced manufacturing and signals that companies view Pennsylvania’s workforce and speed as competitive advantages.

Regulatory and policy backdrop

The announcement follows comments from executive vice president and chief financial officer Joseph Wolk reiterating that J&J will continue to innovate to improve patient care while navigating policy shifts such as U.S. drug‑pricing initiatives. Company executives present the new plant as part of a strategy to scale domestic capacity for transformational medicines and advanced therapies, reflecting confidence in the U.S. manufacturing ecosystem and workforce.

Local economic and market context

State and local officials highlight the project’s expected boost to the regional economy during construction and operation, and J&J says the facility will expand its manufacturing, research, distribution and office operations in the state. On markets, the company’s shares are trading with modest movement, reflecting investor attention but not altering the company’s stated manufacturing and R&D priorities.